Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Sen-Jam Pharmaceutical is a medical company developing novel pharmaceutical solutions for large unmet needs using the development pathway. The company focused on improving clinical outcomes for patients battling opioid use disorder, viral respiratory infections from coronaviruses such as COVID-19, and other painful inflammation and toxin-induced conditions, including arthritis, vaccinations, and even the infamous hangover. Sen-Jam Pharmaceutical develops consumer healthcare products that help people stay strong by mitigating common side effects from medicines and everyday living. The company's global scientists have developed a multi-indication patent and FDA-pending product for the prevention of pain and flu-like symptoms for indications not currently being addressed by the FDA OTC Drug Monograph.

Sandoz AG, part of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

Hainan Poly Pharm. Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The firm is specialized in injections and oral solid formulations. Its products include injection, oral solid dosage, dry suspension and active pharmaceutical ingredient (API). The company was founded by Min Hua Fan on July 14, 1992 and is headquartered in Haikou, China.

Zhejiang Puli Pharmaceutical Co., Ltd., established on 2003-08-13, Business scope includes licensed projects:Drug Wholesale;Drug retail;pharmaceutical production;Production of Class II Medical Devices;food production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Import and export;Pharmaceutical special equipment sales;Machinery sales;Metal Material Sales;food sales(Only sell prepackaged food);Chemical product sales(No licensed chemical products);Sales of electronic components and electromechanical components;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Belina Pharma AB researches, develops, markets, and trades drugs against breast cancer. The company is headquartered in Helsingborg, Sweden.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Shenzhen Jiu Ming Pharmaceutical Co., Ltd., established on 2003-08-14, Business scope includes general business items:Class I medical supplies,cosmetic,Stationery,Sales of sporting goods;property management;housing lease;Cleaning Services;Provide management services for catering;Domestic Trade(Does not contain franchise,Exclusive control,Monopoly);car sales;car rental;Daily necessities retail;Medical device research and development,Elderly equipment(equipment)research and development;Operating non-woven products.(Business operations involving pre-administrative licensing,Can operate only after obtaining pre-administrative licensing documents),The licensing program is:Disinfectant,Healthy food,drug development,Production,Sales;Chinese herbal medicine,Chinese Herbal Medicine,Chinese patent medicine,Chemical API,Chemicals,Antibiotic API,antibiotic preparation,biochemical drug,Biological product(In addition to vaccines),Second Class Psychotropic Drugs(preparation),Anabolics,Wholesale of peptide hormones;Three types of injection and puncture devices,Medical polymer materials and products,Medical electronic equipment,Clinical Laboratory Analytical Instruments,Medical hygiene materials and dressings,Ophthalmic Surgical Instruments,Medical electronic equipment,Medical Optics,Instruments and endoscopic equipment(Excluding contact lenses and their care solutions),Medical Ultrasonic Instruments and Related Equipment,Physiotherapy and Rehabilitation Equipment,medicalXX-ray equipment,Extracorporeal circulation and blood treatment equipment,operating room,emergency room,Consulting room equipment and appliances,medical cold therapy,low temperature,Refrigeration equipment and appliances,Dental materials,Medical Suture Materials and Adhesives;Class II Neurosurgical Instruments,Orthopedic surgery(orthopedics)Surgical Instruments,Surgical Instruments for Obstetrics and Gynecology,General diagnostic equipment,Chinese medicine equipment,medicalXX-ray accessories and components,Medical testing and basic equipment,Dental equipment and appliances,Ward Nursing Equipment and Appliances,Disinfection and sterilization equipment and sales of prepackaged food;Elder care,Confinement Care,recovery treatment,Import and export.

Hangzhou Saili Pharmaceutical Research Institute Co., Ltd., established on 2000-04-20, Business scope includes technology development,Serve,Achievement transfer:drug,Chemical raw materials,medical instruments,chemical reagent,diagnostic test strips;Serve:Economic Information Consulting(In addition to commodity intermediary)

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Morepen Laboratories Ltd. engages in the manufacture and market of bulk drugs and pharmaceutical formulations. It operates through the following business segments: Global Generics, Finished Formulations, Home Health, and Dr. Morepen. The company was founded by K.B. Suri on December 1, 1984 and is headquartered in New Delhi, India.

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1983 and is headquartered in Mumbai, India.

electrical assembly and switchgear construction is a manufacturer of low-voltage main distribution boards and distribution boards.

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Hefei Medical Technology Co., Ltd., established on 1994-12-16, Business scope includes research and development of biomedicine,technology transfer,technical consulting,Technical Services;Research and development of disinfection products,Production,Sales and Technology Transfer(Removal of hazardous chemicals);Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Established in 1992 as an export-oriented unit (EOU), Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing. We today rank among the top 15 pharmaceutical companies in India and enjoy a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products. Their pharmaceutical solutions include active pharmaceutical ingredients (API), finished dosage forms, new drug discovery (NDD), novel drug delivery systems (NDDS) and contract research and manufacturing services (CRAMS). They are globally present across 70+ countries through alliances, joint ventures and partnerships with globally reputed majors.

Wante Pharmaceutical (Hainan) Co., Ltd., established on 2004-03-09, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Chemical product sales(No licensed chemical products)(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)